Trial
NCT00573989
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI)
Condition
Head and Neck Cancer
Intervention
erlotinib hydrochloride
Why stopped
Drug Supply Issue
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-03